[Latest] Global Lung Tumor Market Size/Share Worth USD 46.3 Billion by 2033 at a 7.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
15 avr. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, April 15, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Lung Tumor Market Size, Trends and Insights By Product (Imaging systems, Biopsy...
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
09 avr. 2024 15h34 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
08 avr. 2024 11h36 HE
|
Revolution Medicines, Inc.
Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in...
Non-Small Cell Lung Cancer (NSCLC) Epidemiology Forecast to 2032 Across Eight Major Markets (US, France, Germany, Italy, Spain, UK, Japan and Urban China)
03 avr. 2024 11h29 HE
|
Research and Markets
Dublin, April 03, 2024 (GLOBE NEWSWIRE) -- The "Non-Small Cell Lung Cancer (NSCLC): Epidemiology Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.Non-small cell lung...
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
28 mars 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Oncology-Based In-Vivo CRO Market Projected for Vigorous Growth, North America Leads Regional Shares
07 mars 2024 12h09 HE
|
Research and Markets
Dublin, March 07, 2024 (GLOBE NEWSWIRE) -- The "Oncology-based In-Vivo CRO Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Global Industry Anticipates Major...
$2+ Bn PD-1 Resistant Head and Neck Cancer Markets - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2022 and 2023-2028F
12 févr. 2024 04h14 HE
|
Research and Markets
Dublin, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ...
Global Precision Oncology Market Report 2023: Technological Innovations Propel Growth Opportunities
30 janv. 2024 11h28 HE
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Global Precision Oncology Market Trends and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. The emergence of...
Bispecific CD3 Molecules in Oncology, 2024 Analytical Handbook - Get Early Insights into Technologies, Startups, Emerging Clinical Trial Results, Drug Approvals, and the Ever-Changing Competitive Landscape
30 janv. 2024 05h12 HE
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Bispecific CD3 Molecules in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.There is a considerable and robust...
Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Forecasts to 2034
25 janv. 2024 09h04 HE
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Non-muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The...